Complete remission after myeloablation with bone-seeking 186Re-HEDP and high-dose melphalan followed by autologous stem cell transplantation in a patient with chemorefractory multiple myeloma.
Wiesmann
A
A
Einsele
H
H
Kanz
L
L
Dohmen
B M
BM
D001842:Bone and Bones / Q000378:metabolism; D018572:Disease-Free Survival; D012968:Etidronic Acid / Q000493:pharmacokinetics / Q000627:therapeutic use*; D006801:Humans; D008558:Melphalan / Q000627:therapeutic use*; D008875:Middle Aged; D009101:Multiple Myeloma / Q000628:therapy*; D019653:Myeloablative Agonists / Q000627:therapeutic use; D009942:Organometallic Compounds / Q000493:pharmacokinetics / Q000627:therapeutic use*; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods*; D011868:Radioisotopes / Q000627:therapeutic use; D012074:Remission Induction / Q000379:methods; D012211:Rhenium / Q000627:therapeutic use; D016879:Salvage Therapy / Q000379:methods; D014182:Transplantation, Autologous
D019653:Myeloablative Agonists; D009942:Organometallic Compounds; D011868:Radioisotopes; C101598:rhenium-186 HEDP; D012211:Rhenium; D012968:Etidronic Acid; D008558:Melphalan